The biosimilar road in inflammatory bowel disease: The right way?

Best Practice and Research: Clinical Gastroenterology

Volumn 28, Issue 3, 2014, Pages 465-471

  Fiorino, Gionata ^a   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Biological products; Biosimilar pharmaceuticals; Inflammatory bowel disease; Infliximab; Post marketing product surveillance

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; CT P 13; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; UNCLASSIFIED DRUG;

ARTICLE; BIOEQUIVALENCE; CLINICAL PRACTICE; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFLAMMATORY BOWEL DISEASE; INFUSION RELATED REACTION; POSTMARKETING SURVEILLANCE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB; POST MARKETING PRODUCT SURVEILLANCE;

BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 84902275395     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2014.04.006     Document Type: Review

References (42)

1. N. Bansback, S. Sizto, H. Sun, S. Feldman, M.K. Willian, and A. Anis Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis Dermatology 219 2009 209 218
2. L. Peyrin-Biroulet, P. Deltenre, N. de Suray, J. Branche, W.J. Sandborn, and J.F. Colombel Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials Clin Gastroenterol Hepatol 6 2008 644 653
3. A. Wiens, R. Venson, C.J. Correr, M.F. Otuki, and R. Pontarolo Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis Pharmacotherapy 30 2010 339 353
4. F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, I. Arijs, and G. Van Assche et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort Gut 58 2009 492 500
5. K. Bodger, T. Kikuchi, and D. Hughes Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data Aliment Pharmacol Ther 30 2009 265 274
6. G. Lapadula, and G.F. Ferraccioli Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues Clin Exp Rheumatol 30 2012 S102 S106
7. Y. Liu, E.Q. Wu, A.G. Bensimon, C.P. Fan, Y. Bao, and A. Ganguli et al. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis Adv Ther 29 2012 620 634
8. European Medicine Agency Procedural advice for users of the centralised procedure for similar biological medicinal products applications 2011 EMA/940451/2011
9. M. Weise, M.C. Bielsky, K. De Smet, F. Ehmann, N. Ekman, and G. Narayanan et al. Biosimilars-why terminology matters Nat Biotechnol 29 2011 690 693
10. Comparability of biotechnological/biological products: Note for guidance on biotechnological/biological products subject to changes in their manufacturing process 2003 ICH Topic Q5E
11. European Medicine Agency Similar biological medicinal products containing biotechnology-derived proteins as active substance:quality issues 2005 EMA/CHMP/BWP/49348/2005
12. European Medicine Agency Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues 2005 EMA/CHMP/BWP/42832/2005
13. European Medicine Agency Procedural advice for users of the centralised procedure for similar bio-logical medicinal products applications 2013 EMA/940451/2011
14. Danese S., Florino G. & Michetti P. Are IBD specialists aware of biosimilar monoclonal antibodies? Results from a survey among ECCO members. 9th Congress of ECCO, Copenhagen Denmark, February 20-22, 2014. Available at: https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2014/item/ dop078-are-ibd-specialists-aware-of-biosimilar-monoclonal-antibodies-results- from-a-survey-among-ecco-members.html.
15. H. Schellekens Immunologic mechanisms of EPO-associated pure red cell aplasia. Best practice & research Clin Haematol 18 2005 473 480
16. World Health Organization Guidelines on evaluation of similar biotherapeutic products (SBPs) 2009 [accessed on 02.12.13] http://www.who.int/ biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010. pdf
17. D.H. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, and S. Shevchuk et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Ann Rheum Dis 72 2013 1613 1620
18. D.H. Yoo, N. Prodanovic, J. Jaworski, P. Miranda, E. Ramiterre, and A. Lanzon et al. Efficacy and safety of CT-P13 (Infliximab Biosimilar) over two years in patients with rheumatoid arthritis: comparison between CONTINUED CT-P13 and switching from Infliximab to CT October 26-30, 2013 ACR/ARHP Annual Meeting San Diego, US Available at: https://ww2.rheumatology.org/apps/MyAnnualMeeting/ Abstracts?SearchString=biosimilar&Day=-1
19. W. Park, P. Miranda, M. Brzosko, P. Wiland, S. Gutierrez-Urena, and Y.A. Lee et al. Efficacy and safety of CT-P13 (Infliximab Biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from Infliximab to CT-P13 October 26-30, 2013 ACR/ARHP Annual Meeting San Diego, US Available at: https://ww2.rheumatology.org/apps/ MyAnnualMeeting/Abstract/39201
20. W. Park, P. Hrycaj, S. Jeka, V. Kovalenko, G. Lysenko, and P. Miranda et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Ann Rheum Dis 72 2013 1605 1612
21. G. Van Assche, S. Vermeire, V. Ballet, F. Gabriels, M. Noman, and G. D'Haens et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial Gut 61 2012 229 234
22. L. Peyrin-Biroulet, G. Fiorino, A. Buisson, and S. Danese First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 10 2013 345 351
23. I. Ordas, B.G. Feagan, and W.J. Sandborn Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change Gut 60 2011 1754 1763
24. D.T. Rubin, O. Uluscu, and R. Sederman Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data Inflamm Bowel Dis 18 2012 2225 2231
25. G. Van Assche, S. Vermeire, and P. Rutgeerts The potential for disease modification in Crohn's disease Nat Rev Gastroenterol Hepatol 7 2010 79 85
26. European Medicines Agency Inflectra 2013 [accessed on 29.08.13] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002778/smops/Positive/human-smop-000531.jsp&mid=WC0b01ac058001d127
27. European Medicines Agency Remsima 2013 [accessed on 29.08.13] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002576/smops/Positive/human-smop-000532.jsp&mid=WC0b01ac058001d127
28. S. Danese, and F. Gomollon ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD) J Crohn's Colitis 7 2013 586 589
29. H.C. Ebbers, S.A. Crow, A.G. Vulto, and H. Schellekens Interchangeability, immunogenicity and biosimilars Nat Biotechnol 30 2012 1186 1190
30. A. Mikhail, and M. Farouk Epoetin biosimilars in europe: five years on Adv Ther 30 2013 28 40
31. M. Weise, M.C. Bielsky, K. De Smet, F. Ehmann, N. Ekman, and T.J. Giezen et al. Biosimilars: what clinicians should know Blood 120 2012 5111 5117
32. C.K. Schneider Biosimilars in rheumatology: the wind of change Ann Rheum Dis 72 2013 315 318
33. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G.D'. Haens, and A. Carbonez et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003
34. J.D. Isaacs, J. Greenwood, and H. Waldmann Therapy with monoclonal antibodies. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function J Immunol 161 1998 3862 3869
35. Y. Li, Q. Liu, P. Wood, and A. Johri Statistical considerations in biosimilar clinical efficacy trials with asymmetrical margins Stat Med 32 2013 393 405
36. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, and J.F. Colombel et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
37. W. Reinisch, W.J. Sandborn, P. Rutgeerts, B.G. Feagan, D. Rachmilewitz, and S.B. Hanauer et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies Inflamm Bowel Dis 18 2012 201 211
38. European Medicines Agency Remicade - EPAR product information 2013 [accessed on] http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000240/human-med-001023.jsp&mid=WC0b01ac058001d124
39. D. Tracey, L. Klareskog, E.H. Sasso, J.G. Salfeld, and P.P. Tak Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
40. W.J. Sandborn, J.F. Colombel, B.E. Sands, P. Rutgeerts, S.R. Targan, and R. Panaccione et al. Abatacept for Crohn's disease and ulcerative colitis Gastroenterology 143 2012 62 69 e4
41. W.J. Sandborn, S.B. Hanauer, S. Katz, M. Safdi, D.G. Wolf, and R.D. Baerg et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
42. K.B. Gecse, R. Khanna, G.R. van den Brink, C.Y. Ponsioen, M. Lowenberg, and V. Jairath et al. Biosimilars in IBD: hope or expectation? Gut 62 2013 803 807